Aim immunotech reports second quarter 2022 financial results and provides corporate update

– on track to commence phase 2 study for lead program evaluating ampligen® (rintatolimod) for the treatment of pancreatic cancer in q3 2022
AIM Ratings Summary
AIM Quant Ranking